<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04375878</url>
  </required_header>
  <id_info>
    <org_study_id>AZ-CF2002</org_study_id>
    <nct_id>NCT04375878</nct_id>
  </id_info>
  <brief_title>OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis</brief_title>
  <official_title>OPTION 2: A Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis; With an Extension Phase Evaluation of Immediate Release MS1819 Capsules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AzurRx BioPharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AzurRx BioPharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to assess the safety and efficacy of MS1819 in&#xD;
      enteric capsules vs porcine pancreatic enzyme replacement therapy (PERT) in patients with&#xD;
      exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF). The exploratory&#xD;
      objective of the extension phase (EP) is to find a dose of MS1819 in immediate release&#xD;
      capsules that is safe and results in CFA values in a therapeutic range.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, open-label, multicenter, 2, 2x2 crossover study assessing the safety and&#xD;
      efficacy of MS1819, 2240 mg/day vs porcine PERT, and 4480 mg/day vs porcine PERT given at the&#xD;
      same dose and dosing regimen that was being administered during the pre-study period. MS1819&#xD;
      will be administered in enteric capsules.&#xD;
&#xD;
      MS1819 will be assessed in a 2x2 crossover including approximately 30 patients completing&#xD;
      both periods. Fifteen patients will be randomized to the MS1819 2240 mg/day vs PERT arm, and&#xD;
      15 patients will be randomized to the MS1819 4480 mg/day vs PERT arm. Patients in each arm&#xD;
      will further be randomized to receive either the sequence consisting of MS1819 for 3 weeks&#xD;
      followed by PERT for another 3 weeks or the opposite sequence of treatments, PERT for 3 weeks&#xD;
      followed by MS1819 for another 3 weeks.The coefficient of fat absorption (CFA) will be&#xD;
      measured at the end of each 3 week study period. Patients enrolled into the extension phase&#xD;
      (EP) will be composed of patients who have completed the crossover phase of OPTION 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2020</start_date>
  <completion_date type="Actual">April 8, 2021</completion_date>
  <primary_completion_date type="Actual">April 8, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>2, 2x2 Crossover</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of MS1819 by number of subjects reporting 1 or more adverse events</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of subjects reporting 1 or more adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of MS1819: Coefficient of fat absorption (CFA)</measure>
    <time_frame>6 weeks</time_frame>
    <description>The primary efficacy endpoint is the CFA that will be assessed at the end of each 3-week treatment period. CFAs for MS1819 will be compared to the CFAs of PERT using descriptive methods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stool weights</measure>
    <time_frame>6 weeks</time_frame>
    <description>The relative efficacy of MS1819 compared to porcine PERT will be assessed using stool weights.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Signs and symptoms of malabsorption</measure>
    <time_frame>6 weeks</time_frame>
    <description>The relative efficacy of MS1819 compared to porcine PERT will be assessed using signs and symptoms of malabsorption. The signs and symptoms of malabsorption will include stool frequency, stool consistency, bloating, abdominal pain, flatulence, incidence of visible oil/grease in stool, increased stool quantity and worsening of overall bowel habit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coefficient of Nitrogen Absorption (CNA)</measure>
    <time_frame>6 weeks</time_frame>
    <description>CNA that will be assessed at the end of each 3-week treatment period. CNAs for MS1819 will be compared to the CNAs of PERT using descriptive methods.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Exocrine Pancreatic Insufficiency (EPI)</condition>
  <condition>Cystic Fibrosis (CF)</condition>
  <arm_group>
    <arm_group_label>MS1819 2240 mg/day vs PERT arm,</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in arm will further be randomized to receive either the sequence consisting of MS1819 for 3 weeks followed by PERT for another 3 weeks or the opposite sequence of treatments, PERT for 3 weeks followed by MS1819 for another 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MS1819 4480 mg/day vs PERT arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in arm will further be randomized to receive either the sequence consisting of MS1819 for 3 weeks followed by PERT for another 3 weeks or the opposite sequence of treatments, PERT for 3 weeks followed by MS1819 for another 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MS1819</intervention_name>
    <description>MS1819 in enteric capsules. It contains is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.</description>
    <arm_group_label>MS1819 2240 mg/day vs PERT arm,</arm_group_label>
    <arm_group_label>MS1819 4480 mg/day vs PERT arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Porcine PERT</intervention_name>
    <description>Porcine PERT is being used a comparator to MS1819 as a second drug/intervention.</description>
    <arm_group_label>MS1819 2240 mg/day vs PERT arm,</arm_group_label>
    <arm_group_label>MS1819 4480 mg/day vs PERT arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Cystic fibrosis, based on 2 clinical features consistent with CF, plus either a&#xD;
             new/historic sweat chloride ≥60 mmol/L (measured while not on a CFTR modulator) or&#xD;
             genotype.&#xD;
&#xD;
          2. Under stable dose of porcine PERT&#xD;
&#xD;
          3. A fair or better nutritional status&#xD;
&#xD;
          4. Fecal elastase &lt;100 µg/g&#xD;
&#xD;
          5. Standard-of-care medications including CFTR modulators are allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or diagnosis of fibrosing colonopathy&#xD;
&#xD;
          2. Any chronic diarrheal illness unrelated to pancreatic insufficiency&#xD;
&#xD;
          3. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥5 ×upper&#xD;
             limit of normal (ULN), or total bilirubin level ≥1.5 ×ULN at the Screening visit&#xD;
&#xD;
          4. Feeding via an enteral tube during 6 months before screening&#xD;
&#xD;
          5. Forced expiratory volume ≤30% at the Screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigator Site 105</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 102</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 107</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 101</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 111</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 108</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 103</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 110</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 104</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 106</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 205</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 203</name>
      <address>
        <city>Karpacz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 206</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 202</name>
      <address>
        <city>Rabka-Zdrój</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 204</name>
      <address>
        <city>Sopot</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 30, 2020</study_first_submitted>
  <study_first_submitted_qc>May 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exocrine Pancreatic Insufficiency</keyword>
  <keyword>EPI</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>CF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

